Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
139 hedge funds and large institutions have $709M invested in Merrimack Pharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 52 increasing their positions, 35 reducing their positions, and 19 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
95% more call options, than puts
Call options by funds: $2.91M | Put options by funds: $1.49M
49% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 35
11% more capital invested
Capital invested by funds: $637M → $709M (+$72.5M)
0% more funds holding
Funds holding: 139 → 139 (0)
0% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$39M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$5.78M |
| 3 |
Renaissance Technologies
New York
|
+$4.22M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$2.99M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$2.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$11.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.13M |
| 3 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
-$3.34M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.07M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$2.56M |
MACK Hedge Fund Activity: Q1 2016 in Review
139 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q1 2016, worth a combined $709M — up 11% from $637M a quarter earlier.
Fund positioning in MACK was balanced in Q1 2016: 19 funds opened new positions, 19 closed out, 52 added to existing stakes and 35 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $39M. The largest seller was Millennium Management, exiting entirely with an estimated $11.2M sold.
- 139 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $709M of Merrimack Pharmaceuticals, Inc. stock for Q1 2016, up 11% quarter-over-quarter.
- 19 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q1 2016 and 19 closed out, a net change of 0 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q1 2016 was Consonance Capital Management, an estimated $39M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q1 2016 was Millennium Management, an estimated $11.2M sold.
Based on aggregated 13F filings for Q1 2016.